Biopharma

Recent quotes from pharma CEOs about the effects of President Trump’s potential policy actions clearly point to added elements of risk and uncertainty for the industry. This comes at a time when industry executives are already facing a myriad of difficult challenges. CEO quotes focus on pricing and innovation & intellectual property (IP) issues, these being the life-blood of any pharma ...

The surprise election of Donald Trump as President of the United States has thrown greater uncertainty into many industries and individual companies on the receiving end of his verbal comments during speeches, interviews, and tweets. One industry in particular has received special attention – US pharma. President Trump’s comments about the high price of drugs, allowing direct federal government ...

The movement toward measuring patient outcomes resulting from a specific drug therapy, especially in an environment increasingly focused on specialty medicines, has caused researchers to look at different datasets than previously analyzed. Two patient-based datasets in particular come to mind: 1.) electronic health records (EHR), and 2.) claims data. These two data sources will each be suited to ...